Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 104

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 104
---
 Executive Officer & Chief Financial Officer |

Pursuant to the requirements of the Securities
Act of 1933, as amended, this Post-Effective Amendment No. 2 to the Registration Statement on Form F-1 has been signed by the following
persons in the capacities and on the date indicated.

| Name and Signature    
 /s/ Stephen Stamp     | Title(s)                                                     
 Chief Executive Officer & Chief Financial Officer, Director  | Date              
 November 17, 2025 |
|:----------------------|:-------------------------------------------------------------|:------------------|
| Stephen Stamp         | -Principal Executive Officer and Principal Financial Officer |                   |
| *                     | Non-Executive Chairman of the Board                          | November 17, 2025 |
| Stephen Parker        |                                                              |                   |
| *                     | Senior Independent Non-Executive Director                    | November 17, 2025 |
| Simon Turton, Ph.D.   |                                                              |                   |
| *                     | Non-Executive Director                                       | November 17, 2025 |
| Sijmen de Vries, M.D. |                                                              |                   |
| *                     | Non-Executive Director                                       | November 17, 2025 |
| Ann Merchant          |                                                              |                   |

| *By: | /s/ Stephen Stamp |
|      | Stephen Stamp     |
|      | Attorney-in-fact  |

| 55 |

<div align='center'>AUTHORIZED REPRESENTATIVE</div>

Pursuant
to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment
No. 2 to the Registration Statement on Form F-1 has been signed by the undersigned on this
17th day of November, 2025.

| By:    | /s/ Donald J. Puglisi                          |
| Name:  | Donald J. Puglisi                              |
| Title: | Authorized Representative in the United States |

| 56 |

<div align='center'>Exhibit Index</div>

| Exhibit 
 Number  
 3.1     
 4.1     |     | Title                                                                                                                                                                                                 
 Articles of Association of Biodexa Pharmaceuticals PLC, adopted on June 11, 2025 (incorporated by reference to Exhibit 1.1 to the Company’s Report on Form 6-K, filed with the SEC on June 13, 2025). 
 Description                                                                                                                                                                                           
 of Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to Exhibit